| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
CARLSBAD, Calif.—Seeking to expand its PCR portfolio, LifeTechnologies Corp. has made a three-year collaboration Woburn, Mass.-basedbiotech BioTrove Inc. permanent by agreeing to acquire the company for anundisclosed sum.
 
The acquisition, announced Nov. 10, marries BioTrove'sOpenArray technology, a high-throughput gene expression and genotyping analysissystem, with Life Technologies' line of assay products. John Gerace, vicepresident and general manager of Life Technologies' PCR Systems business, saysthe acquisition will allow the company to build on the synergies experiencedduring a genotyping collaboration that began in 2007.
 
 
"We had an OEM agreement in which we sold their platform andarrays with our genotyping content on it," Gerace says. "We were presented withthe option for putting genotyping and gene expression on the same platform, soan acquisition made obvious sense."
 
 
According to Life Technologies, the increased adoption ofnext-generation sequencing platforms, such as the SOLiD System, has generatedgreater use of qPCR for simultaneous validation of an increased number of genetargets. OpenArray, which is based on an array format that enables researchersto perform more than 3,000 PCR genotyping or qPCR gene expression assays at atime, has the flexibility to allow for samples to be validated against a largetarget panel, or a larger quantity of samples to be screened against selectvalidated targets. The technology is also used in applied markets, such aspathogen testing, and may enable future digital PCR applications.
 
"We have well over 1 million gene expression assays and wellover 5 million genotyping assays, and until now, we only had the ability to putthem into a 384-well microplate or card," Gerace adds. "This acquisition givesus a higher density format in which to put more content and gives our customersthe ability to have a much greater density of up to 3,000 wells in a microscopeslide format."
 
Although Life Technologies did not disclose the financialterms of the deal, the company said it does not expect the transaction to havea material effect on its financials this fiscal year. The acquisition issubject to customary closing conditions.
 
Created in November 2008 by the combination of InvitrogenCorp. and Applied Biosystems Inc., Life Technologies has been very active inthe M/A arena, and Gerace indicates that additional acquisitions may be on thehorizon.
 
"We have a robust, strategic roadmap that will be acombination of our internal development as well as an aggressive M/A strategy,"he says.
 
 
BioTrove was available for comment. Gerace said theacquisition is unlikely to affect BioTrove's staff or existing location inMassachusetts.
 
 
Following the news, Life Technologies' stock hit a 52-weekhigh. Late-trading shares stood at $50.21, up 34 cents from the previous day'sclose. The stock's 52-week range had been $19.56 to $49.99.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue